ATLANTA, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the quarter ended September 30, 2016.
Highlights
* U.S. revenue increased 24% in the third quarter of 2016 compared to the third quarter of 2015
* International revenue increased 11% in the third quarter of 2016 compared to the third quarter of 2015.